(S (NP-SBJ (JJ Inorganic) (NN lead)) (VP (VBZ activates) (NP (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (JJ primary) (JJ human) (JJ CD4+) (NN T) (NNS lymphocytes))))) (. .))
(S (NP-SBJ (NP (JJ Inorganic) (NN lead)) (PRN (-LRB- -LRB-) (NP (NN Pb)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ ubiquitous) (JJ environmental) (NN contaminant)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ (-NONE- *T*-1)) (VP (VBZ produces) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS effects)) (PP (IN on) (NP (ADJP-COOD (ADJP (JJ humoral)) (CC and) (ADJP (NN cell) (JJ mediated))) (JJ immune) (NNS responses))))))))))) (. .))
(S (NP-SBJ (NP (DT The) (VBG underlying) (JJ molecular) (NN mechanism)) (PP (IN for) (NP (NP (NP (NN Pb) (POS 's)) (JJ complex) (NNS effects)) (PP (IN on) (NP (DT the) (JJ immune) (NN system)))))) (VP (VBP remain) (ADJP-PRD (JJ obscure))) (. .))
(S (NP-SBJ-2 (NP (JJ Many)) (PP (IN of) (NP (NP (NP (NN Pb) (POS 's)) (NNS effects)) (PP (IN on) (NP (DT the) (JJ immune) (NN system)))))) (VP (MD could) (VP (VB be) (VP (VBN explained) (NP (-NONE- *-2)) (PP (IN through) (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN factor)) (, ,) (NP (NN NF-kappa) (NN B))))))))) (. .))
(S (NP-SBJ (NN NF-kappa) (NN B)) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ critical) (PP (IN for) (NP (NN T) (NN lymphocyte) (NN function))))) (CC and) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ strong) (NN inducer)) (PP (IN of) (NP (NN HIV-LTR) (NN activation)))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN Pb)) (PP (IN at) (NP (ADJP (RB physiologically) (JJ relevant)) (NNS concentrations)))) (VP (VBZ activates) (NP (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (JJ primary) (JJ human) (JJ CD4+) (NN T) (NNS lymphocytes)))))))) (. .))
(S (NP-SBJ-3 (NP (JJ Pb-induced) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBZ is) (VP (VBN blocked) (NP (-NONE- *-3)) (PP (IN by) (NP-LGS (NP (NNS antibodies)) (PP (IN for) (NP-COOD (NP (NP-COOD (NP (NN p65)) (CC and) (NP (NN p50))) (NNS subunits)) (CONJP (CC but) (RB not)) (NP (NN cRel)))))) (, ,) (S (NP-SBJ (-NONE- *)) (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ-5 (NP (DT the) (NN p65:p50) (NN heterodimer)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN involved) (NP (-NONE- *-5)))))))))) (. .))
(S (NP-SBJ-6 (NP (JJ Functional) (NN activation)) (PP (IN of) (NP (NN gene) (NN expression))) (PP (IN by) (NP (NN Pb)))) (VP (VBD was) (VP (VBN confirmed) (NP (-NONE- *-6)) (S (NP-SBJ (-NONE- *)) (VP (VBG using) (NP (NP (JJ primary) (JJ CD4+) (NN T) (NNS cells)) (VP (VBN transfected) (NP (-NONE- *)) (PP (IN with) (NP (DT an) (ADJP (NP (NN NF-kappa) (NN B)) (JJ dependent)) (NN reporter) (NN gene) (NN construct))))))))) (. .))
(S (NP-SBJ (NN Pb)) (VP (VBD did) (RB not) (VP (VB activate) (NP (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (CD 4) (JJ different) (NN T) (NN cell) (NNS lines)))) (, ,) (S (NP-SBJ (-NONE- *)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (JJ lymphoid) (NN cell) (NNS lines)) (VP (MD may) (RB not) (VP (VB be) (NP-PRD (NP (JJ reliable) (NNS surrogates)) (PP (IN for) (NP (NP (DT the) (NN study)) (PP (IN of) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN in) (NP (JJ human) (NN T) (NNS cells)))))))))))))))) (. .))
(S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN NF-kappa) (NN B)) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT an) (JJ important) (JJ molecular) (NN mediator)) (PP (IN of) (NP (JJ Pb-induced) (NN immunotoxicity))))))))) (. .))
